The state of California currently has 929 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: OPN - Oncology Physician Network, Arcadia, California +9 locations
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
NCT06445114
Recruiting
This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California +3 locations
Conditions: Oropharyngeal Cancer, Carcinoma
Register for Updates
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947
Recruiting
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of California Davis, Sacramento, California
Conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
NCT06228482
Recruiting
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Metastatic Nonsmall Cell Lung Cancer
Register for Updates
Impact of Protect Your Colon™ on CRC Screening
NCT05929820
Recruiting
The purpose of the research is to assess the impact of Protect Your Colon™, a colorectal cancer (CRC) screening decision aid, on patients' CRC screening behaviors. The Investigators hypothesize that Protect Your Colon™, through optimizing shared decision making, will lead to selection of a test that accurately matches patients' values and increase CRC screening uptake. To test this hypothesis, the investigators will conduct a pilot randomized controlled trial (RCT) to assess if provision of Prot... Read More
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
05/21/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Colorectal Cancer Screening
Register for Updates
Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)
NCT06225414
Recruiting
The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hi... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/21/2025
Locations: UCI Health Family Health Center - Anaheim, Anaheim, California +9 locations
Conditions: Lung Cancer
Register for Updates
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
NCT04145141
Recruiting
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their med... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of California, San Diego (UCSD), La Jolla, California +1 locations
Conditions: Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
Register for Updates
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT03808337
Recruiting
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Natera, Inc. (Data and Specimen Analysis Only), San Carlos, California
Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Salinas Valley Memorial Healthcare System, Salinas, California
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
Molecular Analysis for Precision Surgery in Thyroid Cancer Trial
NCT06235814
Recruiting
Ideal surgical extent for differentiated thyroid cancer remains unclear. Routine use of molecular analysis in biopsy-proven thyroid cancer could provide important prognostic information to help guide extent of surgery - thyroid lobectomy versus total thyroidectomy. This is a pilot feasibility study for the use of routine molecular analysis in Bethesda V and VI thyroid cancers, with randomization of the intermediate-molecular risk subgroup to thyroid lobectomy and total thyroidectomy. The investi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Papillary Thyroid Cancer
Register for Updates
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
Recruiting
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the format... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +84 locations
Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian High Grade Endometrioid Adenocarcinoma
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: University of California Los Angeles - Jonsson Comprehensive Cancer Center,201 S. Buena Vista Street, Suite 200, Burbank, California +11 locations
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates